At a glance
- Originator Millennium Pharmaceuticals
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors; Platelet activating factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 15 May 2001 Discontinued-Preclinical for Asthma in USA (Unknown route)
- 31 Aug 1998 No-Development-Reported for Asthma in USA (Unknown route)
- 29 Aug 1996 New profile